利拉鲁肽对高糖诱导足细胞损伤后相关蛋白mRNA和蛋白表达的影响及其机制

doi:10.13481/j.1671-587X.20210204

摘要/Abstract

摘要： 目的

观察胰高血糖素样肽1（GLP-1）受体激动剂利拉鲁肽对高糖诱导足细胞损伤后相关蛋白mRNA及蛋白表达的影响，并探讨其作用机制。

方法

将分化成熟的足细胞随机分为对照组、高糖组、甘露醇对照组、利拉鲁肽组和高糖+利拉鲁肽组。提取各组细胞RNA，应用Real-time PCR（RT-PCR）法检测各组足细胞中Nephrin、Podocin和ZO-1 mRNA表达水平，Western blotting法检测各组细胞中Nephrin、Podocin、ZO-1、Bcl-2和caspase-3蛋白表达水平，免疫荧光法观察足细胞中骨架蛋白Synaptopodin表达情况，流式细胞术检测细胞凋亡率。将分化成熟的足细胞随机分为对照组、高糖组、高糖+利拉鲁肽组、高糖+利拉鲁肽+LY294002组。采用Western blotting法检测磷脂酰肌醇3-激酶（PI3K）/蛋白激酶B（PI3K/Akt）信号通路转导蛋白、Bcl-2和caspase-3表达水平。

结果

与对照组比较，高糖组足细胞中标志蛋白Nephrin、Podocin和ZO-1 mRNA及蛋白表达水平降低（P <0.05），Bcl-2蛋白表达水平降低（P<0.05），caspase-3蛋白表达水平升高（P<0.05），足细胞特异性骨架蛋白Synaptopodin荧光强度明显降低（P<0.05），足细胞凋亡率明显升高（P<0.05）。与高糖组比较，高糖+利拉鲁肽组足细胞中Nephrin、Podocin和ZO-1 mRNA及蛋白表达水平升高（P <0.05），Bcl-2蛋白表达水平升高（P <0.05），caspase-3蛋白表达水平降低（P<0.05），足细胞特异性骨架蛋白Synaptopodin荧光强度明显升高（P<0.05），足细胞凋亡率明显降低（P<0.05）。与对照组比较，高糖组足细胞中PI3K和pAkt蛋白表达水平明显降低（P <0.05），Bcl-2蛋白表达水平降低（ P<0.05），caspase-3蛋白表达水平升高（P <0.05）；与高糖组比较，高糖+利拉鲁肽组足细胞内PI3K和磷酸化Akt（p-Akt）蛋白表达水平明显升高（P <0.05），凋亡相关蛋白Bcl-2蛋白表达水平升高（P <0.05），caspase-3蛋白表达水平降低（P<0.05），与高糖+利拉鲁肽组比较，高糖+利拉鲁肽+LY294002组足细胞中PI3K和磷酸化Akt（p-Akt）蛋白表达水平降低（P<0.05），Bcl-2蛋白表达水平降低（P <0.05），caspase-3蛋白表达水平升高（P<0.05）。

结论

利拉鲁肽通过激活PI3K/Akt信号通路抑制足细胞凋亡，减轻高糖诱导的足细胞损伤。

关键词: 糖尿病肾病, 足细胞, 细胞凋亡, 胰高血糖素样肽1, 利拉鲁肽, 磷脂酰肌醇3-激酶, 蛋白激酶B

Abstract: Objective

To observe the effect of glucagon like peptide-1 （GLP-1） receptor agonist liraglutide on the expressions of the mRNA and protein of related proteins after podocyte injury induced by high glucose， and to explore its mechanism.

Methods

The differentiated mature podocytes were randomly divided into control group， high glucose group， mannitol control group， liraglutide group， high glucose + liraglutide group. The RNA was extracted from cells in each group. Real-time PCR（RT-PCR） was used to detect the expression levels of Nephrin， Podocin and ZO-1 mRNA in the podocytes in various groups. Western blotting method was used to detect the expression levels of Nephrin， Podocin， ZO-1， Bcl-2 and caspase-3 proteins in the podocytes in various groups. The Synaptopodin expression in the podocytes was observed by immunofluorescence method. The apoptotic rate was measured by flow cytometry. The differentiated mature podocytes were randomly divided into control group， high glucose group， high glucose + liraglutide group， high glucose+liraglutide+LY294002 group. The expression levels of the phosphatidylinositol 3-kinase/protein kinase B（PI3K/Akt） signaling pathway proteins were observed by Western blotting method.

Results

Compared with control group， the expression levels of mRNA and protein of the podocytes marker proteins Nephrin， Podocin and ZO-1 in the podocytes in high glucose group were reduced（P<0.05）， the expression level of Bcl-2 proein was reduced（P<0.05）， the expression level of caspase-3 protein was increased（P<0.05）， the fluorescence intensity of specific skeleton protein Synaptopodin was decreased significantly（P<0.05）， and the apoptotic rate of podocytes was increased significantly（P<0.05）. Compared with high glucose group， the expression levels of mRNA and protein of Nephrin， Podocin and ZO-1 in the podocytes in high glucose + liraglutide group were increased（P<0.05）， the expression level of Bcl-2 proein was increased （P<0.05）， the expression level of caspase-3 protein was decreased（P<0.05）， the fluorescence intensity of podocyte specific skeleton protein Synaptopodin was increased significantly（P<0.05）， and the apoptotic rate of podocytes was decreased significantly（P<0.05）. Compared with control group， the expression levels of PI3K and phosphorylated（p-Akt） proteins in the podocytes in high glucose group were decreased significantly （P<0.05）， the expression level of Bcl-2 protein was decreased（P<0.05）， and the expression level of caspase-3 protein was increased（P<0.05）. Compared with high glucose group， the expression levels of PI3K and p-Akt proeins in high glucose + liraglutide group were increased significantly（P<0.05）， the expression level of Bcl-2 proein was increased（P<0.05）， and the expression level of caspase-3 protein was decreased significantly（P<0.05）. Compared with high glucose + liraglutide group， the expression levels of PI3K and p-Akt proteins in the podocytes in high glucose + liraglutide + LY294002 group were decreased（P< 0.05），the expression level of Bcl- 2 protein was decreased（P<0.05），and the expression level of caspase-3 protein was increased（P<0.05）.

Conclusion

Liraglutidecan inhibit the apoptosis of podocytes by activating the PI3K/Akt signaling pathway and alleviates the podocyte injury induced by high glucose.

Key words: diabetic nephropathy, podocyte, apoptosis, glucagon like peptide-1, lilarutide, phosphatidylinositol 3-kinase, protein kinase B

中图分类号:

R587.2

祁冰雪,马彦,张艺献,孙亚东,苗里宁. 利拉鲁肽对高糖诱导足细胞损伤后相关蛋白mRNA和蛋白表达的影响及其机制[J]. 吉林大学学报(医学版), 2021, 47(2): 275-283.

Bingxue QI,Yan MA,Yixian ZHANG,Yadong SUN,Lining MIAO. Effect of liraglutide on expressions of mRNA and protein of related proteins after podocyte injury induced by high glucose and its mechanism[J]. Journal of Jilin University(Medicine Edition), 2021, 47(2): 275-283.

图/表 9

图1

图2

图3

图4

图5

图6

图7

图8

图9

参考文献 30

1	ZAVATTARO M， CAPUTO M， SAMA M T， et al. One-year treatment with liraglutide improved renal function in patients with type 2 diabetes： a pilot prospective study［J］. Endocrine， 2015， 50（3）：620-626.
2	DE LUCAS M D G， BUENO B A， SIERRA J O. Liraglutide preserves renal function in overweight diabetic patients with stage 3 chronic kidney disease［J］. Euro J Int Med，2017， 44：e28-e29.
3	KRISTENSEN S L， RØRTH R， JHUND P S， et al. Cardiovascular， mortality， and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes： a systematic review and meta-analysis of cardiovascular outcome trials［J］. Lancet Diabetes Endocrinol， 2019， 7（10）：776-785.
4	KAWANAMI D， TAKASHI Y. GLP-1 receptor agonists in diabetic kidney disease： from clinical outcomes to mechanisms［J］. Front Pharmacol， 2020， 11：967.
5	ZHANG S S， WU Z， ZHANG Z，et al. Glucagon-like peptide-1 inhibits the receptor for advanced glycation endproducts to prevent podocyte apoptosis induced by advanced oxidative protein products［J］. Biochem Biophys Res Commun， 2017， 482（4）：1413-1419.
6	SHI J X， HUANG Q. Glucagonlike peptide1 protects mouse podocytes against high glucoseinduced apoptosis， and suppresses reactive oxygen species production and proinflammatory cytokine secretion，through sirtuin 1 activation in vitro［J］. Mol Med Rep， 2018， 18（2）： 1789-1797.
7	CHEN P， SHI X Z，XU X， et al. Liraglutide ameliorates early renal injury by the activation of renal FoxO1 in a type 2 diabetic kidney disease rat model［J］. Diabetes Res Clin Pract， 2018， 137：173-182.
8	SIDDIQI F S， MAJUMDER S， THAI K， et al. The histone methyltransferase enzyme enhancer of zeste homolog 2 protects against podocyte oxidative stress and renal injury in diabetes［J］. J Am Soc Nephrol， 2016，27（7）：2021-2034.
9	CARNEY E F. Cholesterol and podocyte injury［J］. Nat Rev Nephrol， 2013， 9（9）：493-493.
10	TANG S C W， YIU W H. Innate immunity in diabetic kidney disease［J］. Nat Rev Nephrol， 2020，16（4）：206-222.
11	HARALOSSON B，NYSTROÖM J，DEEN W M. Properties of the glomerular barrier and mechanisms of proteinuria［ J ］. Physiol Rev， 2008， 88（2）：451-487.
12	SCHIFFER T A， FRIEDERICH-PERSSON M. Mitochondrial reactive oxygen species and kidney hypoxia in the development of diabetic nephropathy［J］. Front Physiol， 2017， 8：211.
13	UMANATH K， LEWIS J B. Update on diabetic nephropathy： core curriculum 2018［ J ］. Am J Kidney Dis， 2018， 71（6）：884-895.
14	LI X， CHUANG PY， D’AGATI V D， et al. Nephrin preserves podocyte viability and glomerular structure and function in adult kidneys［J］. J Am Soc Nephrol， 2015， 26（10）：2361-2377.
15	SAGAR A， ARIF E， SOLANKI A K， et al. Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function［J］. Sci Rep， 2017， 7（1）：12047.
16	KOSTOVSKA I， TOSHESKA-TRAJKOVSKA K， LABUDOVIK D， et al. Nephrin and podocalyxin-markers for early detection of hypertensive nephropathy ［J］. Atherosclerosis Suppl， 2018， 32：132.
17	PONCHIARDI C， MAUER M， NAJAFIAN B. Temporal profile of diabetic nephropathy pathologic changes［J］. Curr Diab Rep， 2013， 13：592-599.
18	IMASAWA T， OBRE E， BELLANCE N， et al. High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy［J］. Faseb J， 2017， 31（1）：294-307.
19	WEIL E J， LEMLEY K V， MASON C C， et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy［J］. Kidney Int， 2012， 82（9）：1010-1017.
20	SHARMA R， MCDONALD T S， ENG H， et al. In vitro metabolism of the glucagon-like peptide-1 （GLP-1）-derived metabolites GLP-1（9-36）amide and GLP-1（28-36）amide in mouse and human hepatocytes［J］. Drug Metab Dispos， 2013，41（12）：2148-2157.
21	MANN J F E， ORSTED D D， BUSE J B， et al. Liraglutide and renal outcomes in type 2 diabetes［J］. New Engl J Med， 2017， 377（22）：2197-2198.
22	YIN W， JIANG Y， XU S， et al. Protein kinase C and protein kinase A are involved in the protection of recombinant human glucagon‐like peptide‐1 on glomeruli and tubules in diabetic rats［J］. J Diabetes Investig， 2019， 10：613-625.
23	LILJEDAHL L， PEDERSEN M H， MCGUIRE J N， et al. The impact of the glucagon-like peptide 1 receptor agonist liraglutide on the streptozotocin-induced diabetic mouse kidney proteome［J］. Physiol Rep， 2019， 7（4）：e13994.
24	LI Y K， MA D X， WANG Z M， et al. The glucagon-like peptide-1 （GLP-1） analog liraglutide attenuates renal fibrosis［J］. Pharmacol Res， 2018， 131：102-111.
25	JIA Y， ZHENG Z J，GUAN M P，et al. Exendin-4 ameliorates high-glucose-induced fibrosis by inhibiting the secretion of miR-192 from injured renal tubular epithelial cells［J］. Exp Mol Med， 2018， 50（5）：1-13.
26	MUSKIET M H A， TONNEIJCK L， SMITS M M， et al. GLP-1 and the kidney： from physiology to pharmacology and outcomes in diabetes［J］. Nat Rev Nephrol， 2017， 13（4）：605-628.
27	REN Q， YOU YU S. CD2-associated protein participates in podocyte apoptosis via PI3K/Akt signaling pathway［J］. J Recept Signal Transduct Res， 2016， 36（3）：288-291.
28	WANG Y Y， TANG L Q， WEI W. Berberine attenuates podocytes injury caused by exosomes derived from high glucose-induced mesangial cells through TGFβ1-PI3K/AKT pathway［J］. Eur J Pharmacol， 2018， 824：185-192.
29	谢海平,林帆,陈彦,等利拉鲁肽治疗2型糖尿病合并非酒精性脂肪性肝病的研究进展[J].临床肝胆病杂志,2020,36(9):2111-2114.
30	李德伦,吴玲玲,董哲毅,等.小檗碱治疗肾脏疾病研究现状[J].解放军医学杂志,2020,45(10):1092-1098.

[1]	刘翠兰,李建军,姜贺,刘晶,王丹,李晨,赵娣. 尿石素B对人神经胶质瘤U118 MG细胞生物学行为的影响及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 566-574.
[2]	冯佳,徐海婵,温健,吴泽华,陈琦. 桦木酸通过调控JAK2/STAT3信号通路对骨髓瘤细胞增殖和凋亡的影响及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 615-622.
[3]	巩培,刘竟然,赵世敏,王玉珍,谢基明. MCM10沉默对乳腺癌MDA-MB-231细胞的增殖抑制作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(3): 652-659.
[4]	李晓辉,瞿紫微,卢昕,孟庆彬,陈华涛,任骏,谭成沛. 骨髓间充质干细胞来源性外泌体携带miR-196b-5p对结肠癌细胞生物学特性的调控作用[J]. 吉林大学学报(医学版), 2021, 47(3): 660-668.
[5]	邹天琪,柏林,张铮旭,李贺,王春梅,孙靖辉,陈建光,陈曦,张成义. 毛樱桃总黄酮对小鼠皮肤增生性瘢痕的抑制作用及其机制[J]. 吉林大学学报(医学版), 2021, 47(2): 265-274.
[6]	赵展琦,张程锦,田娟. Ndfip1对铁离子诱导的神经细胞凋亡的抑制作用及其神经保护作用机制[J]. 吉林大学学报(医学版), 2021, 47(2): 338-343.
[7]	唐浩轩,孟楠峰,杜美玲,王伟,何涛. 新型VEGF单克隆抗体与全反式维甲酸联合应用对乳腺癌MCF-7细胞增殖的抑制作用[J]. 吉林大学学报(医学版), 2021, 47(2): 344-351.
[8]	王暖,杨丽娟,代娟娟,王爱丽,武艳,刘成霞. MARCH1通过PI3K/AKT信号通路对人胃癌细胞迁移和侵袭的促进作用[J]. 吉林大学学报(医学版), 2021, 47(2): 352-359.
[9]	吴洁,杨学华,马玲,范文强,付冬冬,高晓,左淑飞,梁舒,秦艺璐,王培山,郭金燕. miR-26a-5p通过JAK2/STAT3 信号通路对人类风湿关节炎成纤维样滑膜细胞凋亡的影响[J]. 吉林大学学报(医学版), 2021, 47(2): 460-468.
[10]	张海英,张文馨,赵文静,李伟. 五倍子酸通过调节人肝癌HepG-2细胞线粒体氧化磷酸化对细胞凋亡的诱导作用[J]. 吉林大学学报(医学版), 2021, 47(1): 125-132.
[11]	裴永彬,王桂琦,李卫,姜霞,姜海波,赵增仁. 姜黄素对结直肠癌小鼠肿瘤生长的抑制作用及其PTEN/PI3K/Akt信号通路机制[J]. 吉林大学学报(医学版), 2021, 47(1): 145-151.
[12]	吕美娟,马贤德,任路. 针药并用诱导自噬对ApoE基因敲除小鼠认知功能的影响[J]. 吉林大学学报(医学版), 2020, 46(6): 1124-1130.
[13]	李琪, 徐瑞, 李藤藤, 江一川, 李敏. 吡柔比星对大鼠心肌细胞的损伤作用及其模型建立[J]. 吉林大学学报(医学版), 2020, 46(05): 948-954.
[14]	李伟, 张海峰, 王淼, 霍静, 张颖, 赵翠. 黄芪注射液对睡眠剥夺大鼠心脏的保护作用及其机制[J]. 吉林大学学报(医学版), 2020, 46(05): 998-1003.
[15]	贾答淇, 孔雯聪, 苏荣健, 杜晓媛, 贺武斌. 巨噬细胞刺激1受体抑制剂BMS777607对肺癌细胞增殖和凋亡的影响[J]. 吉林大学学报(医学版), 2020, 46(04): 739-744.